Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial.
| Title: | Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial. |
|---|---|
| Authors: | Ahn HS; Division of Cardiology, Department of Internal Medicine, College of Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.; Ahn JC; Department of Cardiology, Korea University Ansan Hospital, Ansan, Republic of Korea.; Cho JM; Division of Cardiology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University, Seoul, Republic of Korea.; Lim KH; Division of Cardiology, Dong-A University Hospital, Busan, Republic of Korea.; Han SH; Division of Cardiology, Gachon University Gil Hospital, Incheon, Republic of Korea.; Cho YK; Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.; Kim KH; Department of Cardiovascular Medicine, Chonnam National University Medical School/Hospital, Gwangju, Republic of Korea.; Hong SJ; Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.; Lee CJ; Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.; Na JO; Cardiovascular Center, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.; Sung KC; Division of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.; Choi K; Department of Cardiology, H-Plus Yangji Hospital, Seoul, Republic of Korea.; Kim SY; Department of Cardiology, Seoul Medical Center, Seoul, Republic of Korea.; Kim DH; Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Lee HC; Division of Cardiology, Department of Internal Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.; Ihm SH; Division of Cardiology, Department of Internal Medicine, Bucheon St Mary's Hospital and the Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea.; Youn JC; Division of Cardiology, Department of Internal Medicine, College of Medicine, Catholic Research Institute For Intractable Cardiovascular Disease, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.; Choi JY; Division of Cardiology, Daegu Catholic University Medical Center, Daegu, Republic of Korea.; Kim SH; Department of Internal Medicine and Cardiovascular Center, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.; Kim KI; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Sung JH; Division of Cardiology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.; Pyun WB; Division of Cardiology, Department of Internal Medicine, Ewha Womans University Medical Center, Seoul, Republic of Korea.; Kim WS; Cardiovascular Center, Department of Internal Medicine, Kyung Hee University Medical Center, Seoul, Republic of Korea.; Cho JS; Division of Cardiology, College of Medicine, Daejeon St. Mary's Hospital, The Catholic University of Korea, Daejeon, Republic of Korea.; Lee Y; Division of Cardiology, Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Republic of Korea.; Her SH; Department of Cardiology, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Republic of Korea.; Cho EJ; Division of Cardiology, Department of Internal Medicine, College of Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.; Lee EM; Division of Cardiology, Department of Internal Medicine, Wonkwang University Sanbon Hospital, Gunpo, Republic of Korea.; Lee HY; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Yoon YW; Division of Cardiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.; Lee JH; Department of Cardiology, Kyungpook National University Hospital, Daegu, Republic of Korea.; Kim W; Division of Cardiovascular, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, Republic of Korea.; Rhee SJ; Division of Cardiology, Department of Internal Medicine, Wonkwang University Hospital, Iksan, Republic of Korea.; Shin J; Division of Cardiology, Department of Internal Medicine, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea. |
| Source: | Journal of clinical hypertension (Greenwich, Conn.) [J Clin Hypertens (Greenwich)] 2026 May; Vol. 28 (5), pp. e70279. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study |
| Language: | English |
| Journal Info: | Publisher: Wiley Periodicals Inc Country of Publication: United States NLM ID: 100888554 Publication Model: Print Cited Medium: Internet ISSN: 1751-7176 (Electronic) Linking ISSN: 15246175 NLM ISO Abbreviation: J Clin Hypertens (Greenwich) Subsets: MEDLINE |
| Imprint Name(s): | Publication: : [Hoboken, NJ] : Wiley Periodicals Inc.; Original Publication: Greenwich, CT : Le Jacq Communication, Inc., c1999- |
| MeSH Terms: | Amlodipine*/administration & dosage ; Amlodipine*/adverse effects ; Amlodipine*/therapeutic use ; Telmisartan*/administration & dosage ; Telmisartan*/adverse effects ; Essential Hypertension*/drug therapy ; Essential Hypertension*/physiopathology ; Antihypertensive Agents*/administration & dosage ; Antihypertensive Agents*/adverse effects ; Antihypertensive Agents*/therapeutic use ; Hypertension*/drug therapy; Blood Pressure/drug effects ; Humans ; Middle Aged ; Male ; Female ; Double-Blind Method ; Treatment Outcome ; Aged ; Drug Combinations ; Adult ; Dose-Response Relationship, Drug |
| Abstract: | Low-dose single-pill combinations (SPCs) are gaining recognition as an efficient therapeutic strategy for mild hypertension. However, evidence from randomized controlled trials regarding the efficacy and safety of half-dose telmisartan/amlodipine SPCs remains limited. In this randomized, double-blind, active-controlled phase III trial, patients with essential hypertension [mean sitting systolic blood pressure (MSSBP) ≥ 140 and < 180 mmHg] were allocated to four treatment arms to receive either telmisartan/amlodipine 20/2.5 mg SPC (TEL/AML 20/2.5), or monotherapy with telmisartan 20 mg (TEL 20), amlodipine 2.5 mg (AML 2.5), or telmisartan 40 mg (TEL 40) once daily for 8 weeks. The primary endpoint was the change in MSSBP from baseline to week 8. A gatekeeping approach was used to test the superiority of TEL/AML 20/2.5 over TEL 20 and AML 2.5, followed by non-inferiority versus TEL 40. At week 8, TEL/AML 20/2.5 showed significantly greater MSSBP reductions compared with TEL 20 [least squares mean (LSM) differences: -5.79 mmHg; p = 0.0003] and AML 2.5 (-8.57 mmHg; p < 0.0001). Non-inferiority to TEL 40 was established, with an LSM difference of -3.88 mmHg (95% Confidence Interval: -6.67 to -1.09), which met the pre-specified 3 mmHg margin. The overall incidence of adverse events was 8.05%, with no statistically significant differences between groups. Overall, TEL/AML 20/2.5 SPC provided superior BP-lowering efficacy compared with TEL 20 and AML 2.5 monotherapies and was non-inferior to TEL 40. With a comparable safety profile across treatment groups, these findings suggest that TEL/AML 20/2.5 is a practical and effective option for hypertension management. Trial Registration: ClinicalTrials.gov, NCT06052748.; (© 2026 The Author(s). The Journal of Clinical Hypertension published by Wiley Periodicals LLC.) |
| References: | K. T. Mills, A. Stefanescu, and J. He, “The Global Epidemiology of Hypertension,” Nature Reviews Nephrology 16, no. 4 (2020): 223–237, https://doi.org/10.1038/s41581‐019‐0244‐2.; Global Cardiovascular Risk Consortium; C. Magnussen, F. M. Ojeda, et al., “Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality,” New England Journal of Medicine 389, no. 14 (2023): 1273–1285, https://doi.org/10.1056/NEJMoa2206916.; J. Lu, Y. Lu, X. Wang, et al., “Prevalence, Awareness, Treatment, and Control of Hypertension in China: Data From 1.7 Million Adults in a Population‐Based Screening Study (China PEACE Million Persons Project),” Lancett 390, no. 10112 (2017): 2549–2558, https://doi.org/10.1016/S0140‐6736(17)32478‐9.; M. Satoh, T. Ohkubo, K. Miura, et al., “Long‐Term Risk of Cardiovascular Mortality According to Age Group and Blood Pressure Categories of the Latest Guideline,” Hypertension Research 48, no. 4 (2025): 1428–1433, https://doi.org/10.1038/s41440‐025‐02151‐w.; S. Oparil, M. C. Acelajado, G. L. Bakris, et al., “Hypertension,” Nature Reviews Disease Primers (2018): 18014, https://doi.org/10.1038/nrdp.2018.14.; V. L. Roger, A. S. Go, D. M. Lloyd‐Jones, et al., “Heart Disease and Stroke Statistics–2012 Update: A Report From the American Heart Association,” Circulation 125, no. 1 (2012): e2–e220, https://doi.org/10.1161/CIR.0b013e31823ac046.; N. C. D. Risk Factor Collaboration. Worldwide Trends in Hypertension Prevalence and Progress in Treatment and Control From 1990 to 2019: A Pooled Analysis of 1201 Population‐Representative Studies With 104 Million Participants. Lancet 2021;398(10304):957–980, https://doi.org/10.1016/S0140‐6736(21)01330‐1.; Sprint Research Group; J. T. Wright, , J. D. Williamson, et al., “A Randomized Trial of Intensive versus Standard Blood‐Pressure Control,” N Engl J Med Nov 373, no. 22 (2015): 2103–2116, https://doi.org/10.1056/NEJMoa1511939.; T. Inoue, “Unawareness and Untreated Hypertension: A Public Health Problem Needs to be Solved,” Hypertension Research 48, no. 4 (2025): 1639–1642, https://doi.org/10.1038/s41440‐025‐02118‐x.; J. An, T. Luong, L. Qian, et al., “Treatment Patterns and Blood Pressure Control With Initiation of Combination versus Monotherapy Antihypertensive Regimens,” Hypertension 77, no. 1 (2021): 103–113, https://doi.org/10.1161/HYPERTENSIONAHA.120.15462.; S. H. Kim, D. W. Shin, S. Kim, et al., “Prescribing Patterns of Antihypertensives for Treatment‐Naive Patients in South Korea: From Korean NHISS Claim Data,” International Journal of Hypertension 2019 (2019): 4735876, https://doi.org/10.1155/2019/4735876.; K. Marinier, P. Macouillard, M. de Champvallins, N. Deltour, N. Poulter, and G. Mancia, “Effectiveness of Two‐Drug Therapy versus Monotherapy as Initial Regimen in Hypertension: A Propensity Score‐Matched Cohort Study in the UK Clinical Practice Research Datalink,” Pharmacoepidemiology and Drug Safety 28, no. 12 (2019): 1572–1582, https://doi.org/10.1002/pds.4884.; B. M. Egan, S. E. Kjeldsen, K. Narkiewicz, R. Kreutz, and M. Burnier, “Single‐Pill Combinations, Hypertension Control and Clinical Outcomes: Potential, Pitfalls and Solutions,” Blood Pressure 31, no. 1 (2022): 164–168, https://doi.org/10.1080/08037051.2022.2095254.; P. Joseph, G. Roshandel, P. Gao, et al., “Fixed‐Dose Combination Therapies With and Without Aspirin for Primary Prevention of Cardiovascular Disease: An Individual Participant Data Meta‐Analysis,” Lancett 398, no. 10306 (2021): 1133–1146, https://doi.org/10.1016/S0140‐6736(21)01827‐4.; G. Parati, S. Kjeldsen, A. Coca, W. C. Cushman, and J. Wang, “Adherence to Single‐Pill versus Free‐Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta‐Analysis,” Hypertension 77, no. 2 (2021): 692–705, https://doi.org/10.1161/HYPERTENSIONAHA.120.15781.; G. Roshandel, M. Khoshnia, H. Poustchi, et al., “Effectiveness of Polypill for Primary and Secondary Prevention of Cardiovascular Diseases (PolyIran): A Pragmatic, Cluster‐Randomised Trial,” Lancet 394, no. 10199 (2019): 672–683, https://doi.org/10.1016/S0140‐6736(19)31791‐X.; K. Tsioufis, R. Kreutz, G. Sykara, J. van Vugt, and T. Hassan, “Impact of Single‐Pill Combination Therapy on Adherence, Blood Pressure Control, and Clinical Outcomes: A Rapid Evidence Assessment of Recent Literature,” Journal of Hypertension 38, no. 6 (2020): 1016–1028, https://doi.org/10.1097/HJH.0000000000002381.; S. Yusuf, P. Joseph, A. Dans, et al., “Polypill With or Without Aspirin in Persons Without Cardiovascular Disease,” New England Journal of Medicine 384, no. 3 (2021): 216–228, https://doi.org/10.1056/NEJMoa2028220.; S. E. Kjeldsen, F. H. Messerli, C. E. Chiang, P. A. Meredith, and L. Liu, “Are Fixed‐Dose Combination Antihypertensives Suitable as First‐Line Therapy?,” Current Medical Research and Opinion 28, no. 10 (2012): 1685–1697, https://doi.org/10.1185/03007995.2012.729505.; T. Unger, C. Borghi, F. Charchar, et al., “International Society of Hypertension Global Hypertension Practice Guidelines,” Hypertension 75, no. 6 (2020): 1334–1357, https://doi.org/10.1161/HYPERTENSIONAHA.120.15026.; B. Williams, G. Mancia, W. Spiering, et al., “ESC/ESH Guidelines for the Management of Arterial Hypertension,” European Heart Journal 39, no. 33 (2018): 3021–3104, https://doi.org/10.1093/eurheartj/ehy339.; S. S. Billecke and P. A. Marcovitz, “Long‐Term Safety and Efficacy of Telmisartan/Amlodipine Single Pill Combination in the Treatment of Hypertension,” Vascular Health and Risk Management 9 (2013): 95–104, https://doi.org/10.2147/VHRM.S40963.; K. C. Ferdinand and S. A. Nasser, “A Review of the Efficacy and Tolerability of Combination Amlodipine/Valsartan in Non‐White Patients With Hypertension,” American Journal of Cardiovascular Drugs 13, no. 5 (2013): 301–313, https://doi.org/10.1007/s40256‐013‐0033‐4.; H. C. Kim, H. Lee, H. H. Lee, et al., “Korea Hypertension Fact Sheet 2024: Nationwide Population‐Based Analysis With a Focus on Young Adults,” Clinical Hypertension 31 (2025): e11, https://doi.org/10.5646/ch.2025.31.e11.; R. M. Guthrie, “Review: A Single‐Pill Combination of Telmisartan Plus Amlodipine for the Treatment of Hypertension,” Postgraduate Medicine 123, no. 6 (2011): 58–65, https://doi.org/10.3810/pgm.2011.11.2495.; R. M. Guthrie, B. Dahlof, K. A. Jamerson, et al., “Efficacy and Tolerability of Telmisartan plus Amlodipine in Added‐Risk Hypertensive Patients,” Current Medical Research and Opinion 27, no. 10 (2011): 1995–2008, https://doi.org/10.1185/03007995.2011.616490.; T. W. Littlejohn, 3rd, C. R. Majul, R. Olvera, et al., “Telmisartan Plus Amlodipine in Patients With Moderate or Severe Hypertension: Results From a Subgroup Analysis of a Randomized, Placebo‐Controlled, Parallel‐Group, 4×4 Factorial Study,” Postgraduate Medicine 121, no. 2 (2009): 5–14, https://doi.org/10.3810/pgm.2009.03.1972.; S. Neldam, M. Lang, R. Jones, and T. Investigators, “Telmisartan and Amlodipine Single‐Pill Combinations vs Amlodipine Monotherapy for Superior Blood Pressure Lowering and Improved Tolerability in Patients With Uncontrolled Hypertension: Results of the TEAMSTA‐5 Study,” The Journal of Clinical Hypertension(Greenwich) 13, no. 7 (2011): 459–466, https://doi.org/10.1111/j.1751‐7176.2011.00468.x.; M. R. Law, N. J. Wald, J. K. Morris, and R. E. Jordan, “Value of Low Dose Combination Treatment With Blood Pressure Lowering Drugs: Analysis of 354 Randomised Trials,” BMJ : British Medical Journal 326, no. 7404 (2003): 1427, https://doi.org/10.1136/bmj.326.7404.1427.; C. K. Chow, E. R. Atkins, G. S. Hillis, et al., “Initial Treatment With a Single Pill Containing Quadruple Combination of Quarter Doses of Blood Pressure Medicines versus Standard Dose Monotherapy in Patients With Hypertension (QUARTET): A Phase 3, Randomised, Double‐Blind, Active‐Controlled Trial,” Lancet 398, no. 10305 (2021): 1043–1052, https://doi.org/10.1016/S0140‐6736(21)01922‐X.; S. R. Gnanenthiran, N. Wang, G. L. Di Tanna, et al., “Association of Low‐Dose Triple Combination Therapy vs Usual Care With Time at Target Blood Pressure: A Secondary Analysis of the TRIUMPH Randomized Clinical Trial,” JAMA Cardiology 7, no. 6 (2022): 645–650, https://doi.org/10.1001/jamacardio.2022.0471.; A. Rodgers, A. Salam, W. Cushman, et al., “Rationale for a New Low‐Dose Triple Single Pill Combination for the Treatment of Hypertension,” Glob Heart 19, no. 1 (2024): 18, https://doi.org/10.5334/gh.1283.; U.S. Food and Drug Administration (FDA) Twynsta Statistical Review(s). 2008, Accessed . https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/22401s000statr.pdf.; T. W. Littlejohn, 3rd, C. R. Majul, R. Olvera, et al., “Results of Treatment With telmisartan‐amlodipine in Hypertensive Patients,” The Journal of Clinical hypertension (Greenwich) 11, no. 4 (2009): 207–213, https://doi.org/10.1111/j.1751‐7176.2009.00098.x.; U.S. Food and Drug Administration (FDA). Non‐inferiority Clinical Trials to Establish Effectiveness: Guidance for Industry 2016, Accessed August 8, 2025. https://www.fda.gov/media/78504/download.; A. J. Manolis, J. L. Reid, D. de Zeeuw, et al., “Angiotensin II Receptor Antagonist telmisartan in Isolated Systolic Hypertension (ARAMIS) Study: Efficacy and Safety of telmisartan 20, 40 or 80 mg versus Hydrochlorothiazide 12.5 mg or Placebo,” Journal of Hypertension 22, no. 5 (2004): 1033–1037, https://doi.org/10.1097/00004872‐200405000‐00027.; S. Neldam, C. Edwards, and A. S. Group, “Telmisartan plus HCTZ vs. amlodipine plus HCTZ in Older Patients With Systolic Hypertension: Results From a Large Ambulatory Blood Pressure Monitoring Study,” The American Journal of Geriatric Cardiology 15, no. 3 (2006): 151–160, https://doi.org/10.1111/j.1076‐7460.2006.05219.x.; P. B. Akat, T. R. Bapat, M. B. Murthy, V. B. Karande, and S. R. Burute, “Comparison of the Efficacy and Tolerability of telmisartan and enalapril in Patients of Mild to Moderate Essential Hypertension,” Indian Journal of Pharmacology 42, no. 3 (2010): 153–156, https://doi.org/10.4103/0253‐7613.66838.; M. Kalikar, K. S. Nivangune, G. N. Dakhale, et al., “Efficacy and Tolerability of Olmesartan, Telmisartan, and Losartan in Patients of Stage I Hypertension: A Randomized, Open‐Label Study,” Journal of Pharmacology and Pharmacotherapeutics 8, no. 3 (2017): 106–111, https://doi.org/10.4103/jpp.JPP_39_17.; C. G. Park, T. H. Ahn, E. J. Cho, et al., “Comparison of the Efficacy and Safety of Fixed‐Dose S‐Amlodipine/Telmisartan and Telmisartan in Hypertensive Patients Inadequately Controlled With Telmisartan: A Randomized, Double‐Blind, Multicenter Study,” Clinical Therapeutics 38, no. 10 (2016): 2185–2194, https://doi.org/10.1016/j.clinthera.2016.09.006.; Lawrence Gould A, S. Unniachan and D. Wu, “Indirect Treatment Comparison Between Fixed‐Dose‐Combinations of amlodipine/losartan and amlodipine/valsartan in Blood Pressure Control,” International Journal of Clinical Practice 68, no. 2 (2014): 163–172.; H. Y. Lee, J. Shin, G. H. Kim, et al., “2018Korean Society of Hypertension Guidelines for the Management of Hypertension: Part II‐Diagnosis and Treatment of Hypertension,” Clinical Hypertension 25 (2019): 20, https://doi.org/10.1186/s40885‐019‐0124‐x.; P. Trenkwalder, D. Elmfeldt, A. Hofman, et al., “The Study on COgnition and Prognosis in the Elderly (SCOPE)—Major CV Events and Stroke in Subgroups of Patients,” Blood Pressure 14, no. 1 (2005): 31–37, https://doi.org/10.1080/08037050510008823.; M. A. Weber, S. Julius, S. E. Kjeldsen, et al., “Blood Pressure Dependent and Independent Effects of Antihypertensive Treatment on Clinical Events in the VALUE Trial,” Lancet 363, no. 9426 (2004): 2049–2051, https://doi.org/10.1016/S0140‐6736(04)16456‐8.; A. Rodgers, A. Salam, A. E. Schutte, et al., “Efficacy and Safety of a Novel Low‐Dose Triple Single‐Pill Combination of Telmisartan, Amlodipine and Indapamide, Compared With Dual Combinations for Treatment of Hypertension: A Randomised, Double‐Blind, Active‐Controlled, International Clinical Trial,” Lancet 404, no. 10462 (2024): 1536–1546, https://doi.org/10.1016/S0140‐6736(24)01744‐6.; D. S. Wald, M. Law, J. K. Morris, J. P. Bestwick, and N. J. Wald, “Combination Therapy versus Monotherapy in Reducing Blood Pressure: Meta‐Analysis on 11,000 Participants From 42 Trials,” American Journal of Medicine 122, no. 3 (2009): 290–300, https://doi.org/10.1016/j.amjmed.2008.09.038.; R. Fogari, A. Zoppi, P. Maffioli, P. Lazzari, A. Mugellini, and G. Derosa, “Effect of telmisartan Addition to amlodipine on Ankle Edema Development in Treating Hypertensive Patients,” Expert Opinion on Pharmacotherapy 12, no. 16 (2011): 2441–2448, https://doi.org/10.1517/14656566.2011.623698.; H. Makani, S. Bangalore, J. Romero, O. Wever‐Pinzon, and F. H. Messerli, “Effect of Renin‐Angiotensin System Blockade on Calcium Channel Blocker‐Associated Peripheral Edema,” American Journal of Medicine 124, no. 2 (2011): 128–135, https://doi.org/10.1016/j.amjmed.2010.08.007.; S. Neldam, D. Zhu, and H. Schumacher, “Efficacy of Telmisartan Plus Amlodipine in Nonresponders to CCB Monotherapy,” International Journal of Hypertension 2013 (2013): 627938, https://doi.org/10.1155/2013/627938.; G. Mancia, R. Kreutz, M. Brunstrom, et al., “2023 ESH Guidelines for the Management of Arterial Hypertension the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA),” Journal of Hypertension 41, no. 12 (2023): 1874–2071, https://doi.org/10.1097/HJH.0000000000003480.; J. W. McEvoy, C. P. McCarthy, R. M. Bruno, et al., “2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension,” European Heart Journal 45, no. 38 (2024): 3912–4018, https://doi.org/10.1093/eurheartj/ehae178.; S. J. Hong, K. C. Sung, S. W. Lim, et al., “Low‐Dose Triple Antihypertensive Combination Therapy in Patients With Hypertension: A Randomized, Double‐Blind, Phase II Study,” Drug Design, Development and Therapy 14 (2020): 5735–5746, https://doi.org/10.2147/DDDT.S286586.; N. Wang, P. Rueter, A. Salam, et al., “Low‐Dose Combinations With 3 or 4 Blood Pressure‐Lowering Medications for the Treatment of Hypertension,” JACC Advances 4, no. 7 (2025):101883, https://doi.org/10.1016/j.jacadv.2025.101883. |
| Grant Information: | Yuhan Corporation |
| Contributed Indexing: | Keywords: hypertension; low‐dose therapy; randomized controlled trial; single‐pill combination; telmisartan/amlodipine |
| Molecular Sequence: | ClinicalTrials.gov NCT06052748 |
| Substance Nomenclature: | 1J444QC288 (Amlodipine); U5SYW473RQ (Telmisartan); 0 (Antihypertensive Agents); 0 (Drug Combinations); 0 (telmisartan amlodipine combination) |
| Entry Date(s): | Date Created: 20260514 Date Completed: 20260514 Latest Revision: 20260516 |
| Update Code: | 20260516 |
| PubMed Central ID: | PMC13172608 |
| DOI: | 10.1111/jch.70279 |
| PMID: | 42130156 |
| Database: | MEDLINE |
Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study